- Home
- NMCO vs DCTH Comparison
NMCO vs DCTH Comparison
Compare NMCO & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMCO
- DCTH
- Stock Information
- Founded
- NMCO 2019
- DCTH 1988
- Country
- NMCO United States
- DCTH United States
- Employees
- NMCO N/A
- DCTH N/A
- Industry
- NMCO Finance/Investors Services
- DCTH Medical/Dental Instruments
- Sector
- NMCO Finance
- DCTH Health Care
- Exchange
- NMCO Nasdaq
- DCTH Nasdaq
- Market Cap
- NMCO 577.1M
- DCTH 630.4M
- IPO Year
- NMCO N/A
- DCTH N/A
- Fundamental
- Price
- NMCO $10.36
- DCTH $13.85
- Analyst Decision
- NMCO
- DCTH Strong Buy
- Analyst Count
- NMCO 0
- DCTH 4
- Target Price
- NMCO N/A
- DCTH $24.00
- AVG Volume (30 Days)
- NMCO 207.6K
- DCTH 531.5K
- Earning Date
- NMCO 01-01-0001
- DCTH 08-04-2025
- Dividend Yield
- NMCO 5.43%
- DCTH N/A
- EPS Growth
- NMCO N/A
- DCTH N/A
- EPS
- NMCO N/A
- DCTH N/A
- Revenue
- NMCO N/A
- DCTH $53,850,000.00
- Revenue This Year
- NMCO N/A
- DCTH $155.42
- Revenue Next Year
- NMCO N/A
- DCTH $37.93
- P/E Ratio
- NMCO N/A
- DCTH N/A
- Revenue Growth
- NMCO N/A
- DCTH 1068.87
- 52 Week Low
- NMCO $8.52
- DCTH $7.17
- 52 Week High
- NMCO $11.64
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- NMCO 42.94
- DCTH 37.03
- Support Level
- NMCO $10.35
- DCTH $15.72
- Resistance Level
- NMCO $10.70
- DCTH $17.35
- Average True Range (ATR)
- NMCO 0.11
- DCTH 0.74
- MACD
- NMCO -0.03
- DCTH -0.40
- Stochastic Oscillator
- NMCO 2.86
- DCTH 2.23
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.